Regeneron receives six months of u.s. pediatric exclusivity for eylea® (aflibercept) injection

Tarrytown, n.y. , oct. 21, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) today announced the u.s. food and drug administration (fda) has granted pediatric exclusivity for eylea® (aflibercept) injection.

REGN Ratings Summary

REGN Quant Ranking